Key facts
- It has raised $19.6M; the latest was Later Stage VC ($8.9M) in Feb 2026.
- Notable investors include Brabantse Ontwikkelings Maatschappij, Rijksdienst voor Ondernemend Nederland, Capricorn Partners, Health Investment Partners, Sioux Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Xyall
- ·The full record, as it builds
Funding rounds
No funding rounds for Xyall are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xyall
Developer of a tissue dissection technology designed to automate and digitize tissue dissection workflow. The company's platform offers accuracy in results, scales with demand, reduces operational cost and risk of cross-contamination, and ensures traceability of each sample and each test, enabling pathologists to obtain reliable molecular diagnostic test results in real-time.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2018
- Employees
- 19
- Website
- xyall.com/
- Ownership
- Privately Held (backing)
Xyall doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xyall shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xyall in its N-PORT filings yet. We sweep new filings monthly.